key: cord-0907538-cepodr91 authors: Weinstock, C.; Flegel, W. A.; Srivastava, K.; Kaiser, S.; Schrezenmeier, H.; Tsamadou, C.; Ludwig, C.; Jahrsdoerfer, B.; Bovin, N. V.; Henry, S. M. title: Erytra Blood Group Analyser and Kode Technology testing of SARS-CoV-2 antibodies among convalescent patients and vaccinated individuals date: 2021-08-28 journal: medRxiv : the preprint server for health sciences DOI: 10.1101/2021.08.26.21262219 sha: 60db5f37d9a7cd49d860abbfe937c633c5bfd1e2 doc_id: 907538 cord_uid: cepodr91 Surveillance of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic requires tests to monitor antibody formation and prevalence. We detected SARS-CoV-2 antibodies using red cells coated by Kode technology with short peptides derived from the SARS-CoV-2 spike protein. Such modified red cells, called C19-kodecytes, can be used as reagent cells in any manual or automated column agglutination assay. We investigated the presence of SARS-CoV-2 antibodies in 130 samples from COVID-19 convalescent plasma donors using standard manual technique, two FDA authorized ELISA assays and a virus neutralisation assay. The sensitivity of the C19-kodecyte assay was 88%, comparable to the anti-SP and anti-NCP ELISAs (86% and 83%) and the virus neutralisation assay (88%). The specificity of the C19-kodecyte assay was 90% (anti-SP 100% and anti-NCP 97%). Likewise, 231 samples from 73 vaccinated individuals were tested with an automated analyser and we monitored the appearance and persistence of SARS-CoV-2 antibodies. The C19-kodecyte assay is a robust tool for SARS-CoV-2 antibody detection. Automated blood group analyser use enables large-scale SARS-CoV-2 antibody testing for vaccination monitoring in population surveys. In the COVID-19 pandemic, tests for virus RNA or virus particles enable the detection and isolation of infected individuals. The proportion of the population carrying antibodies following either infection or vaccination determines the herdimmunity. How long protective antibodies persist after infection or vaccination remains to be determined. Large-scale population screens will provide this valuable information and facilitate the surveillance during the pandemic. Many platforms for SARS-CoV-2 antibody testing have been launched, 1 typically requiring specialized liquid handling and reader devices for result evaluation. We recently developed C19-kodecyte reagent red cells suitable for routine manual and automated assays with the antiglobulin techniques available in most blood bank and hospital laboratories. 2 As many immunohematology laboratories worldwide have automated blood group analysers, they are capable of large-scale testing and uniquely positioned to continuously survey their presumably healthy blood donor populations for COVID-19 immunity. Here we evaluated the C19-kodecyte assay in 130 convalescent plasma donors. The results were compared to established ELISA and a plaque reduction neutralisation assay. 1 In addition, we transferred the C19-kodecyte assay onto an automated blood group analyser and evaluated 231 samples from a vaccination monitoring study. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Informed consent was obtained and individuals were tested for antibodies against SARS-CoV-2 prior to and after vaccination. This study was approved by the ethics board of the University of Ulm (no. 488/20). C19-kodecyte reagent red cells were prepared as previously described. 2 In brief, the Kode constructs FSL-1147 and FSL-1255 were both dispersed in red cell stabilizer solution (ID-Cellstab 005650; Bio-Rad, München, Germany) at concentrations of 1.5 µmol/L and 2.5 µmol/L, respectively. The FSL-1147+1255 construct blend was incubated with washed packed group O red cells for 2 hours at 37 °C, then adjusted to 1 % using red cell stabilizer solution. Serum samples from COVID-19 convalescent donors and controls were manually tested using Grifols DG antiglobulin and saline cards (no. 210342 and 210343, respectively; Grifols S.A., Barcelona, Spain). The cards were used according to the recommendations of the manufacturer. In brief, 25 µl of serum was incubated with 50 µl of 1 % C19-kodecytes in antiglobulin cards. All reactive samples were also tested against untreated cells (the same cells as used to make the kodecytes) in order to exclude reactivity caused by antibodies to natural red cell antigens. In addition, all samples were tested with C19-kodecytes in saline cards in (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 28, 2021. ; https://doi.org/10.1101/2021.08.26.21262219 doi: medRxiv preprint Serum samples from 130 convalescent plasma donors and 38 controls were tested with the C19-kodecyte assay. In the convalescent donor samples, 114 reacted positive with the C19-kodecytes in antiglobulin cards and 9 of these samples also reacted positive in saline cards, indicating the presence of IgM (Fig 2) . Four of the 38 control samples reacted positive with C19-kodecytes in antiglobulin cards (C19-kodecyte reaction grades of 1, 1, 2, 2), with none being reactive in saline cards. All samples were tested with the Euroimmune ELISA. The convalesecent donor samples reactive with the anti-SP-ELISA were additionally tested with the virus neutralization assay. The results were compared to the results of the C19kodecyte assay. The sensitivity of the C19-kodecyte assay was 88 % (Table I), compared to 86 % for the anti-SP IgG ELISA, 83 % for the anti-NCP IgG ELISA, and 88 % for the virus neutralization assay. The specificity of the C19-kodecyte assay was 90 %, while specificity of the ELISA for detecting anti-SP IgG and anti-NCP IgG was 100 % and 97 %, respectively. C19-kodecyte assay reaction grades (Fig 1) , which semi-correlate with antibody levels, 5 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Table II) (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 28, 2021. ; https://doi.org/10.1101/2021.08.26.21262219 doi: medRxiv preprint In this study, we further investigated the novel C19-kodecyte assay designed for the detection of SARS-CoV-2 antibodies. Red cells were coated with short peptides derived from the SARS-CoV-2 spike protein. 2, 6 These red cells laden with artificial SARS-CoV-2 spike antigens (C19-kodecytes) behave like normal red cells bearing blood group antigens in routine antibody screening assays. We first investigated the performance of the C19-kodecyte assay against convalescent plasma donor samples. We then transferred the C19-kodecyte assay onto the Erytra Samples from convalescent donors were tested against a virus neutralisation assay and against two ELISA platforms for the detection of SARS-CoV-2 antibodies. We compared the C19-kodecyte assay (a spike protein anti-IgG assay with limited reactivity to IgM) with the results from these other platforms. Sensitivity (the estimated proportion of subjects with the target condition in whom the test is positive), positive predictive value, and negative predictive value were comparable for the four assays. The calculated specificity (the estimated proportion of subjects without the target condition in whom the test is negative) of the C19-kodecyte assay was lower than that of the ELISA platforms with 4 of 38 samples from individuals without known SARS-CoV-2 infection reacting positive. Although these reactions were caused by IgG binding to the C19-kodecyte reagent red cells, it could not be clarified whether the reaction of these four samples were nonspecific (an unknown specificity reacting against the peptide), or whether the donors had an asymptomatic SARS-CoV-2 infection, or had cross reacting antibodies from previous infections All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 28, 2021. ; https://doi.org/10.1101/2021.08.26.21262219 doi: medRxiv preprint with seasonal alpha and beta-corona viruses. [7] [8] [9] However, this rate was similar to the 91% specificity rate reported previously for the Grifols platform. 2, 6 The samples from negative controls had not been tested with the virus neutralization assay, so a comparison was not possible. Although the majority of convalescent samples reacted positive with all three assays, there were also 31 samples that unexpectedly reacted negative with one or more assays. Eight samples were negative with all three assays suggesting that the level of antibodies in these samples were below the detection threshold. C19kodecytes reacted positive with 15 of these 23 discordant samples (compared with 13/23 for anti-SP ELISA and 9/23 for anti-NCP ELISA) and therefore was unable to detect antibody in only 8 samples that were positive by either or both of the ELISA assays. This divergent reactivity of the C19-kodecyte assay with the ELISA assays has two major probable causes. First, the polyclonal antibody response after infection can differ between individuals, i.e. one individual does not produce antibodies against the same epitopes of the virus as another individual. Therefore, individuals lacking or having lower levels of the antibodies specific for the target used in a specific assay may react negative, while reacting positive with another assay bearing a different target. Secondly, it should be noted that it is the cumulative result of all bound antibodies which is measured in an assay. The C19-kodecyte assay only utilises two linear mono epitopes (MEps) from a domain of the spike protein which is located closely to the virus membrane, 10 whereas the ELISA assays utilise the S1 domain of the spike protein (SP), or a modified nucleocapsid protein (NCP), respectively. ELISA assays with large recombinant proteins are therefore representative of many linear and conformational epitopes and can therefore cumulatively capture many different antibodies (including non-specific antibodies). In (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 28, 2021. ; https://doi.org/10.1101/2021.08.26.21262219 doi: medRxiv preprint kodecyte assays with a consequent potential increase in sensitivity. However, restriction of epitope selection on kodecytes also means a reduction in sensitivity due to the loss of a cumulative effect of detecting multiple different antibodies as occurs with recombinant proteins in ELISA assays. The assay present in this paper is a beta version and ultimately as new knowledge is obtained, the C19-kodecyte assay can be adapted and sensitivity and specificity improved by exchanging or adding new MEps (and adjusting their relative concentrations). This also gives the opportunity for any kodecyte assay to be tuned to bearing the most clinically relevant MEps, an opportunity not readily available to most recombinant protein methodologies. For surveillance and control of the SARS-CoV-2 pandemic, it is necessary to know the current immunity status of the population. Early data on SARS-CoV-2 immunity suggested a rapid decline of the antibody levels, 11, 12 raising questions on the risk of re-infection of convalescents, while others found longer lasting antibody persistence. 13 Testing of large numbers of convalescents and vaccinated people for the collection of large data is required in order to draw meaningful conclusions. The C19-kodecyte assay can support such efforts because it is based on the massscreening indirect antiglobulin technique which is established in all medical laboratories performing immunohematological investigations. We evaluated the C19kodecyte assay on the Grifols Erytra blood group analyser and tested 231 samples from 73 participants of a vaccination study in parallel with patient blood grouping and cross matching, without interference with the laboratory routine. The C19-kodecyte results showed appearance and persistence of antibodies against SARS-CoV-2 in vaccinated individuals. Kodecyte have been previously established to be semiquantitative, 5 and it can be seen that the C19-kodecyte assay also appears to be semi-quantitative, in that serological C19-kodecyte grades are indicative of absent, low and high levels of antibody. Post vaccination the C19-kodecyte grade of most individuals rose to 1+ or 2+. Although not yet established, C19-grades of 2+ maybe indicative of fully immunised status while those with grades of 1+ or less may not yet be optimally immunised. This could be important for future trials in determining the immunisation status/risk of a population. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 28, 2021. ; The C19-kodecyte assay does not require any special equipment, it can be performed manually, although the use of an automated blood group analyser increases the number of samples which can be tested. The Erytra Automated System uses column agglutination cards with 8 reaction columns and is capable of routinely processing at least 50 cards per hour. If just screening for SARS-CoV-2antibody test was to be done with an autocontrol (i.e 4 samples per card), then 200 samples could be tested per hour, especially in times when the analyser otherwise is idle. However, as a positive autocontrol result (being unmodified cells used to make kodecytes) is due to the presence of natural red cell antibodies, the autocontrol need not be done when testing blood donor populations who are already screened for red cell antibodies. Therefore, when screening blood donors 8 samples could be tested per column card, allowing for potentially 400 tests per hour. As the reagent costs for the preparation of the kodecytes are below 0.10 € per test, and implementation is easy, this assay is potentially a valuable tool for the efforts of monitoring population immunity status in the SARS-CoV-2 pandemic. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 28, 2021. ; https://doi.org/10.1101/2021.08.26.21262219 doi: medRxiv preprint Table III All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 28, 2021. ; https://doi.org/10.1101/2021.08.26.21262219 doi: medRxiv preprint Legends to the Figures Fig. 1 The sera were tested by the C19-kodecyte assay using antiglobulin (grey bars) or saline (black bars) gel cards. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 28, 2021. ; https://doi.org/10.1101/2021.08.26.21262219 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Independent side-by-side validation and comparison of four serological platforms for SARS-CoV-2 antibody testing COVID-19 antibody screening with SARS-CoV-2 red cell kodecytes using routine serologic diagnostic platforms COVID-19 antibody detection and assay performance using red cell agglutination. medRxiv Transmission of MERS-coronavirus in household contacts A standardized kodecyte method to quantify ABO antibodies in undiluted plasma of patients before ABO-incompatible kidney transplantation Kodecytes: modifying the surface of red blood cells Preexisting and de novo humoral immunity to SARS-CoV-2 in humans Cross-reactive antibodies after SARS-CoV-2 infection and vaccination. medRxiv No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19 Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections